Tremelimumab is a monoclonal antibody approved in combination with durvalumab and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC).
Tremelimumab combined with durvalumab and platinum-based chemotherapy demonstrated a strong overall survival rate compared with only platinum-based chemotherapy treatment.
The overall response rate of treatment arm one was 39% compared with the response rate of treatment arm three 24%.
Common adverse reactions, which occurred in over 20% of patients, included nausea, fatigue, decreased appetite, musculoskeletal pain, rash, and diarrhea.
Tremelimumab combined with durvalumab efficacious for hepatic carcinoma.